Elias AM, et al. - Via performing this systematic review, researchers sought the evidence in favor of the safety and efficacy of memantine as a treatment for opioid use disorder (OUD). They searched Pubmed (1946-August 2019) and Embase (1947-August 2019) and included one single-blind and five double-blind, placebo-controlled trials in this work. The duration of the studies ranged from 3 to 13 weeks, and memantine dosing ranged from 5 to 60 mg/day. The literature review suggests memantine as the most beneficial adjunctive treatment for OUD when provided in combination with methadone or buprenorphine, but not naltrexone.